BNET Industries

Savient Pharmaceuticals Inc.

(SVNT) is in the Pharma Industry

Market Cap:$891.4M
Last Fiscal Year Sales:$3.1M
  • Public
  • US
Dow Jones Description

We are a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader specialty markets. We are currently developing one product: KRYSTEXXA TM (pegloticase), as a therapy for patients with treatment-failure gout, or TFG, to control hyperuricemia and to manage the signs and symptoms of gout. TFG is gout in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with conventional urate-lowering therapy at the maximum medically appropriate dose or for whom conventional urate-lowering therapy is contraindicated. KRYSTEXXA is a biologic PEGylated uricase enzyme being developed for TFG to control hyperuricemia and to manage signs and symptoms of gout, including the improvement of tophi, improvement in chronic pain, improved physical functioning and decreased frequency of flares. In October 2007, we completed the in-life portion of our two replicate Phase 3 clinical trials of KRYSTEXXA and we are currently conducting an open label extension, or OLE, study in patients who completed the Phase 3 clinical trials. In October 2008, we submitted a Biologic License Application, or BLA, to the U.S. Food and Drug Administration, or FDA, for KRYSTEXXA and in December 2008, the FDA notified us that the BLA was accepted for priority review with a Prescription Drug User Fee Act action, or PDUFA, date of April 30, 2009. ...

Number of Employees 73
Contact Information

1 Tower Center 14th Fl

East Brunswick, New Jersey 08816

savientpharma.c...

(732) 418-9300

NAICS Code Medicinal and Botanical Manufacturing: 325411

Recent Events

  • JPMorgan Starts Savient SVNT at Overweight

    12/04/09 - Bond / Stock Rating - View Story

  • Savient Pharmaceuticals SVNT Reports Q3 Loss of $0.23

    11/05/09 - Financial Announcement - View Story

  • Savient shares rise on takeover speculation

    10/15/09 - Merger / Acquisition - View Story

  • US SMALL/MIDCAPS-Tech stocks lift small, mid caps

    10/09/09 - Bond / Stock Rating - View Story

  • Savient dips, but analyst expects 2010 drug launch

    9/24/09 - Bond / Stock Rating - View Story

  • HEADLINE STOCKS-Some U.S. stocks on the move on Aug. 10

    8/10/09 - Financial Announcement - View Story

News & Analysis

patient and savient pharmaceuticals inc. - All News and Analysis

advertisement
     SVNT $13.20 -0.15 (-1.12% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 1,838,220
Shares Outstanding 66.63M
Market Cap 879.5M
Year High 16.62
Year Low 3.45
Earnings Per Share -2.01
P/E Ratio -6.57
Dividend N/A
Yield N/A
IndustryTop Rated

Brought to you by CBS MoneyWatch.com

advertisement
Click Here
Presented by American Express